Behind BioMed’s Buying Spree

Investors in life science developer BioMed Realty’s parent, a Blackstone Real Estate fund, were in no hurry to cash out and take their profits in 2020 as the pandemic was making the biopharma sector more attractive than ever. So the private equity giant gave them a new, multi-billion-dollar option.